Business Context and Reporting Period
This Form 8-K filing by Sight Sciences, Inc. (SGHT) reports on executive compensation adjustments approved on January 24, 2025. The company is an emerging growth company incorporated in Delaware, with principal offices in Menlo Park, California. The report covers the Compensation Committee's decisions regarding base salaries and cash incentive targets for the fiscal year ending December 31, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures.
| Executive Officer | Fiscal 2024 Base Salary | Fiscal 2025 Base Salary | Target Bonus % |
|---|---|---|---|
| Paul Badawi (CEO) | $640,000 | $659,000 | 75% |
| Alison Bauerlein (CFO) | $450,000 | $473,000 | 60% |
| Matthew Link (CCO) | $420,000 | $433,000 | 50% |
Material Changes
Base salaries for the three named executive officers increased for Fiscal 2025 compared to Fiscal 2024. The increases range from approximately 3.1% to 3.0% across the executives. The target bonus opportunity percentages for Fiscal 2025 were established as 75% for the CEO, 60% for the CFO, and 50% for the CCO.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or general risk factors. However, it specifies that the Fiscal 2025 cash incentive program is contingent upon the achievement of predetermined milestones, including:
- Revenue targets
- Adjusted operating expense goals
- Key market access milestones
- Key clinical and R&D milestones
- Key commercial launch milestones
Investor Verification Checklist
- Verify the specific revenue and expense milestones required to trigger the executive cash bonuses.
- Confirm the status of key clinical and R&D milestones mentioned as bonus criteria.
- Review the company's latest 10-K or 10-Q for actual revenue and operating expense performance against the new targets.
- Check for any subsequent filings regarding the achievement of commercial launch milestones.